Trending

Stories

CureVac’s mRNA Covid Vax Just 47% Effective

Must Read

German biopharmaceutical company CureVac’s mRNA-based vaccine has shown the efficacy of just 47 percent against Coronavirus disease, the lowest reported so far from any Covid-19 vaccine maker.

The trial of vaccine candidate CVnCoV, which included nearly 40,000 volunteers from 10 countries, did not meet pre-specified statistical success criteria, according to the preliminary results of a clinical trial reported on Wednesday.

Also Read

“The variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge,” said Franz-Werner Haas, Chief Executive Officer of CureVac, in a statement.

The vaccine maker assessed 134 Covid-19 cases in this interim analysis. Out of these cases, 124 were sequenced to identify the variant causing the infection. The trial will continue with a minimum of 80 additional cases, and the final analysis is expected in two to three weeks, the company said.

“We’re going full speed for the final readout. We are still planning to filing for approval Haas was quoted as saying by the New York Times.

The results caught scientists by surprise. The vaccine is made from engineered mRNA, the same technology used by the Pfizer-BioNTech and Moderna vaccines. And CureVac’s shots yielded promising results in animal experiments and early clinical trials.

According to Haas, the disappointing results were due to the high number of virus variants in the countries where the vaccine was tested — latin America and Europe. Out of 124 of the Covid-19 cases that the company’s scientists genetically sequenced, only one was caused by the original version of the coronavirus.

More than half of the cases (57 per cent) were caused by Variants of Concern. Most of the remaining cases were caused by other less characterised variants such as Lambda or C37, first identified in Peru (21 per cent) and B1621, first identified in Colombia (7 per cent).

In this context, the company said the company said that the interim results suggest efficacy in younger participants but did not allow to conclude on efficacy in the age group above 60.

The results should serve as a wake-up call for the threat that new variants can pose to the effectiveness of vaccines, Haas was quoted as saying by the NYT. CureVac is searching for new RNA molecules that can work against many variants at once, as well as combining RNA molecules tailored to different variants in a single dose. “It’s a new Covid reality, that’s for sure,” he said.

Stay updated

Subscribe to our newsletter and never miss an update on the latest tech, gaming, startup, how to guide, deals and more.

Latest

Stories

- Advertisement -
- Advertisement -

Latest

Grow Your Business

Place your brand in front of tech-savvy audience. Partner with us to build brand awareness, increase website traffic, generate qualified leads, and grow your business.

- Advertisement -

Related

- Advertisement -
- Advertisement -
Twitter Blue: One-Hour Tweet Editing Window for Subscribers Google Pay Enables Aadhaar-Based UPI Authentication iOS 17: Improved Autocorrect with Personalized On-Device ML OnePlus Nord N30 5G goes official in the U.S. Apple Introduces Vision Pro VR Headset for Augmented and Virtual Reality Microsoft to Pay $20M Fine for Violating Children’s Privacy with Xbox Nothing Phone (2) Confirmed for India Production Fitbit Integration with Google Accounts Begins Xiaomi 13 Ultra Global Launch: Offers, Price, Specs Meta Unveils Quest 3 VR Headset, Reduces Price for Quest 2
Twitter Blue: One-Hour Tweet Editing Window for Subscribers Google Pay Enables Aadhaar-Based UPI Authentication iOS 17: Improved Autocorrect with Personalized On-Device ML OnePlus Nord N30 5G goes official in the U.S. Apple Introduces Vision Pro VR Headset for Augmented and Virtual Reality Microsoft to Pay $20M Fine for Violating Children’s Privacy with Xbox Nothing Phone (2) Confirmed for India Production Fitbit Integration with Google Accounts Begins